17Jun/13

New EXTEND Analyses Evaluate Efficacy Of Single Agent PIXUVRI® In 3rd And … – Daily Markets

New EXTEND Analyses Evaluate Efficacy Of Single Agent PIXUVRI® In 3rd And
Daily Markets
Compared to physicians’ choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30 percent of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 

and more »

17Jun/13

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI(R) in 3rd … – Wall Street Journal (press release)

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI(R) in 3rd
Wall Street Journal (press release)
Compared to physicians’ choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30 percent of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 

and more »

17Jun/13

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI in 3rd and … – MarketWatch (press release)

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI in 3rd and
MarketWatch (press release)
Compared to physicians’ choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30 percent of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 

and more »

17Jun/13

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and … – PR Newswire (press release)

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and
PR Newswire (press release)
Compared to physicians’ choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30 percent of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 

and more »